Reverb Therapeutics Raises USD $12 Million Seed Round Financing to Harness Cytokine Signaling With its Amplify*R™ Platform
Summary
VANCOUVER, British Columbia Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced it has closed a USD $12 Million financing led by founding investor Amplitude Ventures . This approach avoids the hurdles that have blocked other attempts to enlist cytokines to treat disease, which include systemic toxicity, immunogenicity, and manufacturing issues. Reverbs initial focus is on the treatment of cancer and autoimmune diseases.In vivo preclinical studies have established proof-of-concept for the AmplifyR platforms ability to redirect endogenous cytokines and shrink tumors. Reverbs bispecific antibodies amplify and redirect cytokines to tissues of interest, with potential to generate powerful medicines for cancer, autoimmune conditions, and other diseases. Elements of AmplifyR antibodies are reusable, allowing Reverb to rapidly scale its pipeline across multiple disease areas.